Organovo Holdings (ONVO) : Traders are bullish on Organovo Holdings (ONVO) as it has outperformed the S&P 500 by a wide margin of 14.42% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.86%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.31% in the last 1 week, and is up 17.27% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Organovo Holdings (NYSEMKT:ONVO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.60 and $4.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.71. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.55, notching a gain of 5.08% for the day. The total traded volume was 2,302,073 . The stock had closed at $4.33 on the previous day.
The stock has recorded a 20-day Moving Average of 11.27% and the 50-Day Moving Average is 27.79%. Organovo Holdings, Inc. is up 73.66% in the last 3-month period. Year-to-Date the stock performance stands at 82.73%.
Organovo Holdings (ONVO) : 2 Wall Street analysts covering Organovo Holdings (ONVO) believe that the average level the stock could reach for the short term is $4.25. The maximum price target given is $5 and the minimum target for short term is around $4, hence the standard deviation is calculated at $0.35.
Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.